eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
.
.: "fremanezumab for the preventive treatment of chronic migraine."
.
.
.
stephen silberstein, md, director, jefferson university headache center.
.official guidelines say no one should wait more than 62 days to get cancer care after an urgent referral by their gp
https://grassfed.us/Weppler-daughter-of-Phomsoukha-from-Trebon
"there may be subtle differences (between animals and humans) that we don't know about," klein said.
.
eng - english
.
.
.
andrew kaye, head of policy at macmillan cancer support said it was �shocking� that a cancer patient had to wait 541 days for treatment.
.
.
.
.
.